The Impact of Type 2 Diabetes on Mortality in End-Stage Renal Disease Patients Differs between Genders

被引:22
|
作者
Karame, A. [1 ,2 ]
Labeeuw, M. [1 ,2 ]
Trolliet, P. [1 ]
Caillette-Beaudoin, A. [3 ]
Cahen, R. [1 ]
Ecochard, R. [4 ,5 ]
Galland, R. [3 ]
Hallonet, P. [3 ]
Pouteil-Noble, C. [1 ,2 ]
Villar, E. [1 ]
机构
[1] Hosp Civils Lyon, Lyon Sud Hosp, Pierre Benite, France
[2] Univ Lyon 1, F-69622 Villeurbanne, France
[3] Lucien Hussel Hosp, Ctr Associatif Lyonnais Dialyse, Vienne, France
[4] Hosp Civils Lyon, Dept Biostat, Lyon, France
[5] Univ Lyon 1, CNRS, UMR 5558, F-69365 Lyon, France
来源
NEPHRON CLINICAL PRACTICE | 2009年 / 112卷 / 04期
关键词
Dialysis; End-stage renal disease; Type 2 diabetes mellitus; Survival; gender; CARDIOVASCULAR-DISEASE; POPULATION; SURVIVAL; PREVALENCE; PREDICTORS; COHORT; WOMEN; MEN; AGE; US;
D O I
10.1159/000224794
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: In diabetics with end-stage renal disease (ESRD), risk of death has been reported to be non-constant after the first dialysis, and different outcomes have been observed between genders. We assessed the impact of type 2 diabetes (T2DM) on mortality in dialysis regarding its differential effect by gender using time-dependent analyses. Methods: All T2DM and non-diabetic (no-DM) patients who started dialysis in two renal units in Lyon, France, between January 1, 1995, and December 31, 2007, were included. In multivariate analyses, the Cox model and Shoenfeld residual approach were used to assess the effect of T2DM on dialysis mortality by gender. Results: We included 235 T2DM (males: 57.9%) and 480 no-DM (males: 65.6%) patients. In males, the adjusted hazard ratio (aHR) for death in T2DM versus no-DM was 0.83 (p = 0.20) and was constant over time after the first renal replacement therapy (RRT) (p = 0.88). In females, aHR for death in T2DM versus no-DM patients was not constant over time (p = 0.002). It was 0.64 (p = 0.13) within the first year after the first RRT and 2.10 (p = 0.002) after the first year. Evolutions with time of these aHR by gender were significantly different (p = 0.009). Conclusions: T2DM was associated with death only in females. This association was not constant over time after the first dialysis. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:C268 / C275
页数:8
相关论文
共 50 条
  • [1] The impact of glycaemic control on outcomes in patients with end-stage renal disease and type 2 diabetes
    Zoungas, Sophia
    Kerr, Peter G.
    Lui, Michelle
    Teede, Helena J.
    NEPHROLOGY, 2008, 13 (02) : 124 - 127
  • [2] End-stage renal disease in patients with type 1 diabetes
    Lofthouse M.
    Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (1): : 4 - 4
  • [3] Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy
    Mohanram, A
    Zhang, Z
    Shahinfar, S
    Keane, WF
    Brenner, BM
    Toto, RD
    KIDNEY INTERNATIONAL, 2004, 66 (03) : 1131 - 1138
  • [4] Incidence of End-Stage Renal Disease in Patients With Type 1 Diabetes
    Helve, Jaakko
    Sund, Reijo
    Arffman, Martti
    Harjutsalo, Valma
    Groop, Per-Henrik
    Gronhagen-Riska, Carola
    Finne, Patrik
    DIABETES CARE, 2018, 41 (03) : 434 - 439
  • [5] Incidence of end-stage renal disease in patients with type 1 diabetes
    Finne, P
    Reunanen, A
    Stenman, S
    Groop, PH
    Grönhagen-Riska, C
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14): : 1782 - 1787
  • [6] Risk of end-stage renal disease in patients with type 1 diabetes
    Finne, P
    Reunanen, A
    Groop, PH
    Grönhagen-Riska, C
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V241 - V241
  • [7] The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy
    Carides, George W.
    Shahinfar, Shahnaz
    Dasbach, Erik J.
    Keane, William F.
    Gerth, William C.
    Alexander, Charles M.
    Herman, William H.
    Brenner, Barry M.
    PHARMACOECONOMICS, 2006, 24 (06) : 549 - 558
  • [8] The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
    George W. Carides
    Shahnaz Shahinfar
    Erik J. Dasbach
    William F. Keane
    William C. Gerth
    Charles M. Alexander
    William H. Herman
    Barry M. Brenner
    PharmacoEconomics, 2006, 24 : 549 - 558
  • [9] The Impact of Diabetes Mellitus on Vascular Biomarkers in Patients with End-Stage Renal Disease
    Moon, Jeonggeun
    Lee, Chan Joo
    Lee, Sang-Hak
    Kang, Seok-Min
    Choi, Donghoon
    Yoo, Tae-Hyun
    Park, Sungha
    YONSEI MEDICAL JOURNAL, 2017, 58 (01) : 75 - 81
  • [10] Serum transferrin predicts end-stage Renal Disease in Type 2 Diabetes Mellitus patients
    Zhao, Lijun
    Zou, Yutong
    Zhang, Junlin
    Zhang, Rui
    Ren, Honghong
    Lin, Li
    Guo, Ruikun
    Zhang, Jie
    Liu, Fang
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (14): : 2113 - 2124